Table 4.

Clinical presentation at the time of COVID-19 relapse.

	Patients with both recurrent SARS-CoV-2 infection and symptom relapsea
Clinical Features	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7
Age	45	33	4∙5	48	37	29	33
Sex	Male	Male	Female	Female	Female	Male	Male
SARS-CoV-2 negative to positive (days)	11	9	23	22	22	21	8
Date of first admission	2020/1/22	2020/1/25	2020/1/27	2020/2/27	2020/2/3	2020/2/7	2020/2/27
Date of first discharge	2020/2/27	2020/2/26	2020/2/11	2020/3/18	2020/2/20	2020/3/16	2020/3/19
Date of second admission	2020/3/7	2020/3/2	2020/2/26	2020/4/2	2020/3/8	2020/3/31	2020/4/2
Date of second discharge	2020/3/12	2020/3/30	2020/3/4	2020/4/12	2020/3/22	2020/4/8	2020/4/6
Temperature ≥38 °C	No	No	No	No	No	No	No
Fatigue	No	Yes	No	No	No	No	No
Cough	No	Yes	No	Yes	Yes	No	No
Sore throat	Yes	Yes	No	No	No	No	No
Shortness of breath	Yes	Yes	No	No	No	No	No
Nausea/vomiting	No	No	No	No	No	No	No
diarrhea	No	No	No	No	No	No	No
Myalgia/arthralgia	No	Yes	No	No	No	No	No
Chest pain	No	No	No	No	No	No	No
≥2 signs or symptoms	Yes	Yes	No	Yes	No	No	No
Leukocyte (×109 count /L)	6∙89	12∙51	3∙65	6∙85	4∙74	5∙49	5∙75
Hemoglobin (g/L)	143	155	122	124	142	162	161
Lymphopeniab	Yes	Yes	No	No	No	No	No
Thrombocytopeniac	No	No	No	No	No	No	No
Sodium (mmol/L)	140∙7	141∙4	140∙6	137∙7	138	140∙6	137∙1
Potassium (mmol/L)	3∙90	3∙93	3∙68	3∙71	3∙90	3∙76	4∙52
Creatinine ≥133 μmol/L	No	No	No	No	No	No	No
Aspartate aminotransferase >40 U/L	No	No	No	No	No	Yes	No
Alanine aminotransferase >40 U/L	No	No	No	No	No	Yes	No
Total bilirubin ≥17.1 μmol/L	No	Yes	No	No	No	No	No
Creatinine kinase ≥200 U/L	No	No	No	No	No	Yes	No
C-reactive protein level ≥10 mg/L	Yes	Yes	No	No	No	No	No
Lactose dehydrogenase ≥250 U/L	No	No	No	No	No	No	No
D-dimer ≥0∙5 mg/L	No	No	Yes	NA	NA	NA	NA
Activated partial thromboplastin time (seconds)	34∙3	37∙1	36∙5	NA	NA	NA	NA
Prothrombin time (seconds)	11∙3	15∙8	11∙9	12∙3	NA	NA	11∙9
Local patchy shadowing	No	No	NA	No	Yes	No	Yes
Bilateral patchy shadowing	No	Yes	NA	Yes	No	Yes	No
Ground-glass opacities	No	Yes	NA	No	No	Yes	Yes
ARDS	No	No	No	No	No	No	No
Acute renal injury	No	No	No	No	No	No	No
Septic shock	No	No	No	No	No	No	No
Co-infections	No	Yes	No	No	No	No	No
More than one complication	No	No	No	No	No	No	No
Received antibiotic therapy	No	Yes	No	No	No	No	No
Received antiviral therapy	No	Yes	Yes	No	Yes	No	Yes
Use of corticosteroid	No	No	No	No	No	No	No
Clinical recovery	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Cases remained at the hospital	No	No	No	No	No	No	Yes
Discharged	Yes	Yes	Yes	Yes	Yes	Yes	No
Length of stay for the second admission (days)	5	28	7	10	14	8	4

Abbreviations: ARDS, acute respiratory distress syndrome; COVID-19, coronavirus disease; CT, computed tomography; NA, test results not available; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

^aData represent clinical characteristics of patients at second hospitalization on account of recurrent symptomatic infection with SARS-CoV-2.

^bLymphopenia: lymphocyte count <1,500/μL.

^cThrombocytopenia: platelet count <150,000/μL.